Lack Of Cost-Effectiveness Analysis For Products In Development Could Affect Company Valuations, Attorney Mahinka Says
Executive Summary
With payers playing a more prominent role in determining access to drugs, developers will need to focus more on the comparative value of a drug throughout the development cycle, including cost. That value equation also will become an important part of the M&A landscape, attorney Stephen Mahinka says.
You may also be interested in...
PCORI’s Slow Start On Comparative Research May Protect It From Political Heat
The Patient-Centered Outcomes Research Institute’s slow ramp-up to being in a position to fund comparative research projects may actually help it survive a heated political environment in an election year.
Drug Developers Facing "Unsettled" Period Of 5 To 10 Years As CER Environment Evolves, FDA's Woodcock Says
The growing emphasis on comparative effectiveness research as well as the many unknowns on how the process is going to evolve could create a decade of unsettlement for drug development, FDA's Janet Woodcock said
Venture Capitalists Have A Growing Interest In Comparative Effectiveness
Venture capitalists are taking a growing interest in the impact of comparative effectiveness research on future drug products and how results might affect products' ability to gain coverage by third-party payers